$VYGR News

Voyager Therapeutics Issued FDA Clearance For Its Investigational New Drug Application For VY1706 To Treat Alzheimer's Disease

Voyager Therapeutics Q1 EPS $(0.47) Beats $(0.53) Estimate, Sales $2.593M Miss $8.784M Estimate

Voyager Therapeutics To Present Eight Oral And Poster Studies At ASGCT 2026, Including Late‑Breaking GLP Toxicology Data On Investigational Tau‑Silencing Alzheimer's Gene Therapy VY1706 Ahead Of Planned IND Filing In Q2 And First‑In‑Human Dosing In H2 2026

Voyager Therapeutics CFO Nathan Jorgensen Resigns, Effective April May 8

Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript

HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $25 Price Target

Voyager Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.

Voyager Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.

Earnings Breakdown: Voyager Therapeutics Q4

Voyager Therapeutics Q4 EPS $(0.46) Beats $(0.54) Estimate, Sales $15.336M Beat $10.491M Estimate

Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Voyager Therapeutics (VYGR): Strong Q3 Prompts Bullish Coverage

We're A Little Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Rate

HC Wainwright & Co. Maintains Buy on Voyager Therapeutics, Lowers Price Target to $25

Voyager Therapeutics Files For Mixed Shelf Offering Of Up To $400M

Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates

Voyager Therapeutics: Q3 Earnings Snapshot

Voyager Reports Third Quarter 2025 Financial and Operating Results

Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia

Transition Bio Collaborates With Voyager To Advance Small Molecules Targeting TDP-43 In ALS And Frontotemporal Dementia